Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV‑2

• Published in: ACS infectious diseases Vol. 10; no. 9; pp. 3419 - 3429
• Main Authors: Maxwell, Joshua W. C., Stockdale, Skye, Stewart, Erica L., Ashley, Caroline L., Smith, Lachlan J., Steain, Megan, Triccas, James A., Byrne, Scott N., Britton, Warwick J., Ashhurst, Anneliese S., Payne, Richard J.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13.09.2024
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - pharmacology; Adjuvants, Vaccine - administration & dosage; Administration, Intranasal; Animals; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; CD4-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - immunology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Female; Humans; Immunity, Cellular; Lipopeptides - administration & dosage; Lipopeptides - immunology; Mice; Mice, Inbred BALB C; SARS-CoV-2 - immunology; Spike Glycoprotein, Coronavirus - immunology; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - immunology; mucosal vaccine; solid-phase peptide synthesis; SARS-CoV-2; self-adjuvanted vaccine; peptide fusion vaccine; Pam2Cys

Despite concerted efforts to tackle the COVID-19 pandemic, the persistent transmission of SARS-CoV-2 demands continued research into novel vaccination strategies to combat the virus. In light of this, intranasally administered peptide vaccines, particularly those conjugated to an immune adjuvant to...